CGON
CG OncologyCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Successful clinical readouts or a strategic partnership could rapidly re-rate the stock toward premium growth multiples; market attention would likely amplify upside given limited public float and concentrated event risk [#SERP-1].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -12.8.
What can break
Clinical readout failure or delay
Momentum
82
Value
41
Sentiment
36
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $63.80 · Bull $88.77 · Bear $38.84
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $90.29
Why
Momentum82 · Δ7d -12.8
Value41 · Δ7d +0.1
Sentiment36 · Δ7d +0.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
82
26% active weight
Current posture
7d trendSoftening
Δ7d
-12.8
Δ21d
+31.0
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
36
34% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
+0.8
Why this grade
Composite grade C. Momentum 81.8 / Value 41.1 / Sentiment 36.3
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$6.19B
Beta
-
Shares Out
88.2M
P/E (TTM) · Derived
-33.7
P/S (TTM)
1485.68
P/FCF (TTM) · Derived
-35.01
Rev YoY
+1982.7%
EPS YoY
+57.5%
Gross Margin
-63.1%
Op Margin
-8285.3%
Net Debt
-$735.13M
Current Ratio
31.30
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology